Rotavirus vaccine
- Generic Name
- Rotavirus vaccine
- Brand Names
- Rotarix, Rotateq
- Drug Type
- Biotech
- Background
Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain. Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.
- Indication
Rotarix is indicated for prevention of rotavirus gastroenteritis caused by G1, G3, G4, and G9 types in infants aged 6-24 weeks .
Rotateq is indicated for the prevention of rotavirus gastroenteritis caused by G1, G2, G3, G4, and G9 types in infants aged 6-32 weeks .
- Associated Conditions
- Rotavirus Gastroenteritis caused by rotavirus G1, Rotavirus Gastroenteritis caused by rotavirus G2, Rotavirus Gastroenteritis caused by rotavirus G3, Rotavirus Gastroenteritis caused by rotavirus G4, Rotavirus Gastroenteritis caused by rotavirus G9
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- Conditions
- Pneumococcal Immunization
- Interventions
- Biological: PCV21 vaccineBiological: Prevnar 20 vaccineBiological: M-M-R II vaccine
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2320
- Registration Number
- NCT06824194
- Locations
- 🇭🇳
Investigational Site Number : 3400003, Tegucigalpa, Honduras
🇵🇷Investigational Site Number : 6300002, Bayamon, Puerto Rico
🇭🇳Investigational Site Number : 3400001, San Pedro Sula, Honduras
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- Conditions
- Pneumococcal Immunization
- Interventions
- Biological: PCV21 vaccineBiological: Prevnar 20 vaccineBiological: M-M-R II vaccine
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 580
- Registration Number
- NCT06824181
- Locations
- 🇺🇸
The Medici Medical Research- Site Number : 8400008, Hollywood, Florida, United States
🇺🇸Atlantis Clinical Research, LLC- Site Number : 8400009, Miami, Florida, United States
🇺🇸Helios- Site Number : 8400016, Burleson, Texas, United States
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- Conditions
- Pneumococcal Immunization
- Interventions
- Biological: PCV21 vaccineBiological: Prevnar 20 vaccineBiological: M-M-R II vaccineBiological: Hexaxim Vaccine
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1630
- Registration Number
- NCT06736041
- Locations
- 🇺🇸
Eclipse Clinical Research- Site Number : 8400029, Tucson, Arizona, United States
🇺🇸Northwest Arkansas Pediatrics- Site Number : 8400030, Fayetteville, Arkansas, United States
🇺🇸Century Research Institute- Site Number : 8400065, Huntington Park, California, United States
Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants
- Conditions
- Meningococcal ImmunizationHealthy Volunteers
- Interventions
- Biological: Pentavalent Meningococcal ABCYW vaccineBiological: Pneumococcal 13-valent conjugate vaccine
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 750
- Registration Number
- NCT06647407
- Locations
- 🇩🇰
Investigational Site Number : 2080002, Hvidovre, Denmark
🇨🇿Investigational Site Number : 2030007, Plzeň, Czechia
🇨🇿Investigational Site Number : 2030004, Ostrava, Czechia
Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
- Conditions
- RSV Immunization
- Interventions
- Biological: Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccineBiological: Streptococcus pneumoniae vaccineBiological: Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccineBiological: Measles, mumps, and rubella vaccineBiological: Varicella virus vaccineBiological: Placebo
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 2226
- Registration Number
- NCT06397768
- Locations
- 🇲🇽
Investigational Site Number : 4840004, Mexico City, Mexico
🇵🇷Investigational Site Number : 6300004, Trujillo Alto, Puerto Rico
🇺🇸South Alabama Medical Clinic- Site Number : 8400065, Grand Bay, Alabama, United States
Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa
- Conditions
- Meningococcal ImmunisationHealthy Volunteers
- Interventions
- Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate VaccineBiological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate VaccineBiological: Pneumoccocal VaccineBiological: Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)Biological: Measles, Mumps, and Rubella Vaccine live (MMR)Biological: DTaP-IPV-Hib-HepB vaccineBiological: Typhoid conjugate vaccine (TCV)
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1528
- Registration Number
- NCT05794230
- Locations
- 🇮🇳
Investigational Site Number : 3560006, Chennai, India
🇮🇳Investigational Site Number : 3560007, Hyderabad, India
🇮🇳Investigational Site Number : 3560016, Kanpur, India
Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa
- Conditions
- DiarrheaDiarrhea Rotavirus
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Centre for Infectious Disease Research in Zambia
- Target Recruit Count
- 720
- Registration Number
- NCT04658914
- Locations
- 🇿🇲
Chawama first level hospital, Lusaka, Zambia
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
- Conditions
- Infections, Meningococcal
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1196
- Registration Number
- NCT03621670
- Locations
- 🇬🇧
GSK Investigational Site, Edinburg, United Kingdom
Optimising Rotavirus Vaccine in Aboriginal Children
- Conditions
- Viral Gastroenteritis Due to Rotavirus
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Telethon Kids Institute
- Target Recruit Count
- 1000
- Registration Number
- NCT02941107
- Locations
- 🇦🇺
Menzies School of Health Research, Darwin, Northern Territory, Australia
Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
- Conditions
- Rotavirus DiarrheaVaccine Virus SheddingTropical Enteropathy
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 700
- Registration Number
- NCT01375647
- Locations
- 🇧🇩
International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.